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THE SEARCH FOR A CHEMICAL CURE
FOR CANCER*
by
ALASDAIR B. MACGREGOR
I have expressed theopinion that we are at the eve ofa discovery for the arrest, or perhaps, the
cure ofcancer. (Langston Parker)
PARKul1 was commenting on the treatment of cancer by chemical means in 1867,
but hiswords are no more nor less appropriate nowthan theywereahundredyears-
or even a thousand years-ago.
The sophistication of cancer chemotherapy has increased with successive dis-
coveries in the fields of medicine, biology and chemistry, but out of all proportion
to the results in terms ofcure or amelioration.
THE FIRST DEVELOPMENTS
The earliest known account of the treatment of cancer with a chemical substance
is in the Ebers Papyrus2'. written about 1500 B.C. It describes the use of arsenical
ointments in ulcerating lesions that were probably neoplastic. In the fourth century
B.C. Hippocrates2'3recognized from his own observations that cancer was a distinctive
disease. He used caustic pastes and cautery for superficial lesions, but warned that
only these could be successfully treated. Celsuso4in A.D. 30in De Re Medicadescribes
the topical treatment of tumours with a variety of substances as well as excision of
cancer ofthe breast, lip and face.
Porcius Cato2 (234-149 B.C.) used coal in the treatment of cancer and Plinius
Secundus2 (A.D. 23 or 24-79) even tried internal treatment with coal and figs. Galen2,3
the last great physician of the Graeco-Roman school, viewed cancer as a systemic
disease caused by 'black bile' (atra bilis)-he used surgery, diet and purging for
treatment. This is the first glimpse of an alternative view of cancer, for previously
it had always been considered simply as a local lesion.
THE DARK AGES
Little is known of what happened in the succeeding seven centuries, though the
early knowledge was preserved by the Church. The Arabian medical culture was
active during this time, the first great figure to come to prominence was Rhazes,2
born in A.D. 860, who used an ointment containing lead and pepper for superficial
lesions. Avicenna2,4 born in A.D. 980, was the first to advise thespecificuse ofarsenic
for the treatment of cancer. He also recognized the therapeutic value of music.
The Church in Europe remained a dominant factor in western medicine, being the
source of teaching and guardian of manuscripts during the Dark Ages. However, it
did nothing to foster the advance of medicine, and in A.D. 1215, Pope Innocent III
decreed that no priest should perform any operation involving bloodshed. Thus the
* Maccabaean Prize Essay, Faculty of the History of Medicine and Pharmacy, 1966.
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practice of surgery was turned over to the barbers, and other groups oflaymen, the
most notable of whom were the 'itinerants' who wandered throughout Europe,
cutting for stone, cataract and repairing hernias. Arsenic appears to have remained
the specific treatment for cancer at this time; Pope Gregory X was treated with
Fr&re C8me's paste (which contained a large amount of arsenic) for a facial epithe-
lioma. It is said that there was no sign ofrecurrence at his death eight years later in
1276, though he suffered from arsenic poisoning during his treatment.
THE LIGHT OF THE RENAISSANCE
Theodoric of Bologna4 (who later became Bishop of Cervia) was one of the few
churchmen to make hismarkinmedicine, andfollowinghim, theadvance ofmedicine
moved into the hands ofthelaity. Henri de Mondeville2,5 was the first greatphysician
of the Middle Ages. He advised the use of arsenic and zinc chloride pastes for the
treatment of superficial cancer. He was followed by Guy de Chauliac4'6 who rose
from being a peasant's son to become physician to three Popes. He was an out-
standing surgeon, and made considerable advances in the field of diagnosis as well
aswritingChirurgiaMagnawhichremainedtheauthoritativetextduringthethirteenth
and fourteenth centuries, and included a history ofmedicine-the first since Celsus.
He also advised the use ofarsenic, as a paste mixed with clay, for the treatment of
superficial cancers.
The next two hundred years saw the Renaissance, with the gradual evolution of
science, in medicine as well as many other fields. This period culminated in the
publication in 1543 of Vesalius' work on anatomy, coincidental with Copernicus'
work on astronomy. Happily for us, Vesalius' work was read and understood im-
mediately, whereas that ofCopernicus was so complex andlengthythatveryfewhave
ever read it. Ambroise Par634"5 was the greatest surgeon of his time (1510-90). He
was strongly opposed to the use of arsenic in the treatment of cancer because ofits
terrible sideeffects, though forinoperable tumours he used diet and purgation. So too
was Fabricius Hildanus3s45 (Wilhelm Fabry, from Hilden), who proposed instead
the treatment ofbreast cancer by mastectomy and axillary dissection.
One of the most misunderstood and controversial figures of the time was Para-
celsus56 (Philippus von Hohenheim). He was strongly opposed to the use of
'Galenicals', which were mainlyconcoctions ofvariousherbs, so popular atthattime.
He looked for the 'active principles' in drugs, and preferred chemicals to herbs in
his remedies.
THE CULTS OF POLYPHARMACY AND SECRECY
Unfortunately, Paracelsus' ideas were not adopted by the medical profession, and
during the following years many exotic preparations were used in the treatment of
cancer.InA NewPracticalEssayonCancers,Burrows,in1767,afterattackingthe'estab-
lishment' describes current pathology and methods of cure, such as hemlock, night
shade, antimony in various forms, mercury, caustics and bleeding, purging, diet and
exercise. He then goes on to describe the marvellous results he has had from his
own treatment, which he completely omits to describe. It is not surprising that some
unknown hand has written 'a damnedpuffing quack' across the Edinburgh University
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copy, and later when Burrows writes ofhis 'anti-cancerous elixir' has added a foot-
note, 'so that's his famous remedy, the impudent swindler.'
The 'cure' which caused the greatest controversy was that put forward by Storck
in his essay on the medicinal nature of hemlock, published in Edinburgh in 1762.7
When others failed to substantiate his results, he maintained that it was only the true
Vienna hemlock which has this property. Sir John Hill8 obtained seeds ofthe appro-
priate variety, but found his results still inconclusive, andsaid a cure 'whether itever
will or will not be found, remains in the womb of time'. However much one may
deplore St6rck's methods, one must admire his literary style. His paper begins-
'In shady places where the soil is rich; and near ditches, and the fences offields and
meadows; grows an umbelliferous plant, which flowers in the month of July.'
THE DEVELOPMENT OF THE UNDERSTANDING OF CANCER
Advances in general, and particularly in the basic sciences were gathering momen-
tum at this time. Harvey demonstrated the circulation ofthe blood, Zacharias Jans-
sen9 invented the microscope in 1590-which was taken up and improved by a host
of investigators including Malpighi and van Leeuwenhoek. Thomas Sydenham, the
father of English medicine, was the first to prescribe iron for anaemia. Hunter10,
the foremost surgeon-anatomist of the eighteenth century, discusses cancer in his
Lectures on the Principles ofSurgery. He differentiated between 'consequent cancers
in opposition to the original'. He recognized the importance of lymphatic spread
which was first put forward by the Paris surgeon Le Dran (1685-1770).3 Hunter
must have felt the need for a systemically. active cytotoxic agent in the face of
the poor results of surgery at that time, for he was moved to say, 'what I call a
cure is an alteration ofthe disposition and the effect of that disposition and not the
destruction of the cancerous parts. But as we have no such medicine, we are often
obliged to remove cancerous parts; which extirpation, however, will often cure as
well as we could do by changing the disposition and the action.'
At this time there was a remarkable figure, Bernard Peyrilhe. He is credited with
the first attempt to transplant a tumour to an animal-the dog howled so much that
his housekeeper could not bear it, and drowned the doge so the end result is not
recorded. His treatment for carcinoma of the breast was mastectomy, with excision
of pectoralis major and dissection of axillary lymph nodes.3'5 In his Dissertation
acad6mique sur le cancer, in 1776, he maintained that attempts to restore diseased
tissue to normal were not only vain, but absurd. He felt the difficulty in finding a
suitable chemical agent was accounted for by the similarity ofnormal and malignant
tissue, and any agent damaging one is bound to damage the other. His ideas were
intunewiththose ofHunter, and showhowthesurgicalgiants ofthisage werealready
beginning to realize the immense problems involved in the successful treatment of
cancer by drugs. Peyrilhe did however recommend the use of kohlsaure (carbonic
acid) in the treatment ofnasal carcinoma.
THE PROBLEMS OF THE EARLY NINETEENTH CENTURY
The general dissatisfaction with the methods available for the cure of cancer was
reflected in the wide variety of medications that were used as an adjunct to surgical
treatment. Walshell in 1846 gave a long list ofinternal and external remedies which
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were in common use. These included hemlock (or conium), belladonna, digitalis,
antacids, tonics, alteratives (arsenic and mercury) and animal substances-animal
charcoal, cod liver oil, flesh ofgrey lizard, which were all used as internal remedies.
The external remedies in use were preparations oflead, iodine, gastricjuice, carbonic
acid, petroleum, tar products, turpentine, and a variety of escharotics including
caustic potash, silver nitrate and arsenious acid. Rdnnow12 in 1778, described the
cure of30 cases ofcancer in 50 years (Mem. Acad. roy. Sci., Stockholm, 1778) by the
use ofarsenic.
Sir Astley Cooper3'5 in his Lectures on Surgery in 1802 urged medical men to 'the
trial of the numerous agents which chemistry and botany have, of late, abundantly
discovered and simplified'. He also put forward the idea that cure by surgery should
not be relied on alone, but that an attempt should be made 'to alter the constitution
which has not only led to the complaint, but will surely regenerate it, if it remain
unchanged'. He also realized the practical importance of lymphatic spread, and in
The Anatomy ofthe Breast describes all the essential details of lymphatic drainage
as shown by his mercury injection preparations.
In 1805, Young5 suggested the use ofcaustics afterthe excision oftumours, because
he felt that it was impossible to know if any tumour cells were left.
THE DEVELOPMENT OF MODERN CLINICAL INVESTIGATION
This was a period ofaccelerating advance in the basic sciences, many books were
published on morbid anatomy, great strides forward were being made in chemistry,
Currie introduced the clinical thermometer, Auenbrugger discovered the value of
percussion ofthe chest and Laennec invented the stethoscope. These discoveries led
to deeperunderstanding ofdisease processes, while chemistry produced a whole range
of substances to investigate.
THE USE OF ESCHAROnICS
Canquoin1 in 1834 introduced the use ofzinc chloride for the treatment of cancer
byenucleation. Hepublished a series of600cases andclaimed to cure 82%, compared
with a 10% cure rate from excision. Rivalliel advocated the use of 'solidified' nitric
acid, and Filhos1 suggested the use of solid 'potassa cum calce' for treatment of
cancer ofthe neck ofthe uterus in 1847. Gillespie (Edinburgh Monthly Journal, 1856)
put forward the idea that such good results were obtained by the use ofzincchloride,
thatit should be used before surgery, ratherthan as anadjunct to surgery. Broadbent'
suggested the injection ofdilute acetic acid into the tumour itself.
A considerable stir was caused by Dr. Landolfi, a surgeon to the army in Sicily
who proclaimed the efficacy of his treatment of cancer with paste of chloride of
bromide. He made a grand tour of the various leading European medical centres,
modestlydemonstrating hismethod. Heunfortunatelyvariedhistreatmentindifferent
centres, sometimes adding chlorides ofzinc, antimony and gold to his original paste
but without fulfilling the hopes ofhis colleagues and his own extravagant claims. He
was very strongly criticised by Las6gue13 in 1855. Routh" in 1866, described the use
ofbromine in the treatment oftwo cases ofcancer ofthe cervix.
Acomprehensive survey ofthe position in the mid-nineteenthcentury was made by
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Langston Parker' (1867). He discusses most ofthe treatments then in current use and
describes which methods oftreatment he feels are ofvalue in particular situations.
THE SYSTEMIC TREATMENT OF LEUKAEMIA
Two years earlier, a paper of considerable interest was published by Lissauer,14
describing two cases of leukaemia. The first, a woman of 32, was admitted with
advanced disease ofrecent onset, with gross liver and splenic enlargement. Leukaemia
was confirmed by the large number of white cells in the peripheral blood. At the
suggestion of Dr. Rosenkranz, the chief medical officer, she was given Fowler's
solution by way of experiment, because it was known that horses looked healthier
andtheircoatsglossierafterbeinggiven arsenic. Despite the rather doubtful rationale
ofthe treatment, the patient improved, and after a total of five months in hospital,
wasdischarged. Ashorttimeafterthissherelapsedanddied outside, andpost mortem
was not performed. The second case, a man of twenty, left the hospital before he
could be treated. In an earlier number ofthe samejournal, Dr. Valentinerl1 had used
Fowler's solution to cut short the fever in another case of leukaemia, but did not
continue treatment thereafter.
THE BEGINNING OF THE ERA OF SURGERY
Inthelatterpartofthenineteenthcenturythesurgeonreignedsupreme. Anaesthesia
had relieved the immediate agonies of operation, and allowed prolonged procedures
to be attempted. The discoveries of Pasteur and Lister had reduced the horrifying
destruction ofpost-operative infection. Advances in bacteriology and pathology led
to more precise appreciation of disease, while the discovery of Roentgen in 1895
opened up a whole new era of diagnostic refinement. The discovery of radium in
1898 bythe Curies added afurtherweaponto arapidlygrowingtherapeutic armamen-
tarium. Even in this rapidly changing time, Billroth,5 perhaps the leading surgeon of
his period, still used zinc chloride for the treatment ofsuperficial lesions in old, timid
andanaemicpatients. HealsopublishedthereportofacasesomeyearsafterLissauer's
paper, on the treatment of a lymphoblastoma with potassium arsenite, which had
repeated dramatic regressions.8
THE DEVELOPMENT OF ENDOCRINE ABLATION
During the last decade ofthe nineteenth century, thefoundationswere laid for two
lines of attack on cancer. In 1896, Beatson16 described the effect of ovariectomy on
two pre-menopausal patients with advanced cancer of the breast. He had one post-
menopausal patient whom he discussed, but felt that ovariectomy should not be
done. He based his treatment on observations on sheep and cows, on the effects of
pregnancy on their milk production and in the knowledge of reports from abroad
that ovariectomy ofcows whichwerelactatingcausedthem to continuetheirlactation.
He drew the conclusion that the ovaries had some effect on the breast, which was
completely independent of any neurological mediation. He obtained good early
results in the two cases on which he operated. His work was followed up by a series
ofninety-nine cases published by Lett17 in 1905, with quite favourable results.
Other factors in the endocrine field were coming to light. White,8 in 1893, had
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described the regression of uterine fibromas after ovariectomy, and the decrease in
prostatic hypertrophy after bilateral orchidectomy. This latter finding was con-
firmed by several other pioneers in 1895 and 1896. Following these precocious dis-
coveries, there is a blank in the field ofendocrine ablation in the treatment ofcancer
for almost forty years.
THE FIRST STEPS TOWARDS MODERN CANCER CHEMOTHERAPY
The other early move in the battle against cancer was also neglected for many years.
Ehrlich,18 in 1898, described the necrotic effects of an alkylating agent, ethylinimine,
on animal epithelial tissue. Some fifty years later, this same substance was examined
for its cancerocidal properties.
A curiosity of this era was the use of Coley's toxins in the treatment of cancer.2
His observations were made in 1891 and came from the observation that patients
with cancer who developed erysipelas and other acute bacterial infections frequently
had a remission. He, therefore, developed a toxin from the organisms and used it in
the treatment of cancer. In 1909, a series was published with twenty-eight patients
out of 430 surviving for five to fifteen years after treatment. However, this never
became a popular form of treatment because of its severe side effects.
In 1901, Loeb9 published a paper describing the first successful transplantation of
tumours. He used rat sarcoma which he managed to transplant from rat to rat, but
not to mice, guinea pigs or hens. His work was paralleled by that ofJensen in Den-
mark in the same year. These discoveries were of tremendous importance in the
development of an understanding of cancer, and for the assessment of cytotoxic
agents.
In the early part of this century, with the improvement of micro-biological and
biochemical techniques, considerable study was made of the effect of chemicals on
cells. Dixon and Malden in 19088 showed that colchicine had a depressant action on
the bone marrow in human subjects and in 1910, Warburg" studied the effect of
phenylurethane on the fertilized eggs of the sea urchin. He showed that very low
concentrations could arrest mitosis without unduly depressing the oxygen uptake.
In the same year, Ehrlich's enterprise resulted in the introduction of Salvarsan for
clinical use. This sparked off a tremendous drive by the German pharmacologists to
find a suitable metallic compound for the treatment of cancer, so that within a few
years there were a large number ofdrugs on the market. While undoubtedly some of
these did cause necrosis of tumours in experimental animals, unfortunately clinical
experience did not substantiate the optimistic claims of the manufacturers.
A RETURN TO ESCHAROTICS
In 1916,there was arenewed interest in the treatment ofbreast cancerwithcaustics,
when it was realized that the results of surgery were not as good as had been hoped.
Strobell2l published a paper describing his technique of destroying the skin with
potassium hydroxide, while the patient was under an anaesthetic, with full aseptic
precautions, and then necrosing the tumour with zinc chloride. He used skin grafts
to close anylarge defects. He reported a series ofeight cases in which he had obtained
favourable results. Some months later, W. S. Stone5 reviewed the use of caustics,
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and came to the conclusion that it was justified to make a fresh study of their use,
particularly in advanced tumours, because of the high primary mortality and the
high percentage ofrecurrences following operation.
MUSTARD GAS
During the First World War, when an intensive study was made of all means to
kill more men more quickly, mustard gas was discovered and introduced in 1917.
From this inauspicious start has developed one ofthe most important group ofdrugs
for the treatment ofcancer to date, and which has provided the stimulus for what has
now developed into one ofthelargest and mostexciting research projects in medicine.
Throughout the waryears, little was known ofits action, except that it was a vesicant,
its actionbeing mediated by the intracellular release ofhydrochloric acid. In 1919 and
1920, several papers were published describing its depressant action on the haemo-
poietic system, but apart from a few isolated studies over the next twenty years, the
next advance had to await the stimulus ofthe Second World War.
A TRIAL OF LEAD
Shortly after the First World War, there was renewed interest in the treatment of
cancer with lead, caused bythe publication ofa series ofpapers byW. Blair Bell and
his colleagues of their experiences between 1920 and 1926.2223 It all sprang from
observation ofthe abortifacient properties oflead. Theyfound thatleadwas concen-
trated in cells rich in phosphatides, which included chorionic epithelium, embryonic
cells and malignant neoplasms. A special preparation ofcolloidal lead was developed
and given intravenously. In 192624 they were able to publish a series of 229 cases,
ofwhichthey believedthey hadcuredthirty-one, withthe arrest ofthe disease process
in a further ten. By this time they felt they werejustified to say, 'Today we feel it is
not right to prejudice any longer the method by dealing with totally helpless cases-
cases that after trial of every known form of treatment have been sent to us in the
vain hope that the day of miracles is not past.'
THE DEVELOPMENT OF THE ALKYLATING AGENTS
In 1931, a paper was published by Adair and Bagg25 which seems to have attracted
little attention. They reviewed the action of mustard gas on normal skin, and then
went on to examine its action on neoplasms ofthe skin. They proceeded from animal
experiments tolocal application on humantumours, includingepithelioma, malignant
melanoma, neurofibroma and senile warts. Quite favourable results were reported,
except for one patient with a malignant melanoma who died from metastases. They
alsotried anintratumoral injection ofmustard gas to a sarcoma ofthethigh. This was
followed by an intense reaction, with extrusion ofnecrotic material through the skin,
but eventually the tumour was replaced by a fibrous scar. Berenblum et al. in 193626
showed that, in vitro, mustard gas brought aboutdepression of oxygenconsumption,
and ofaerobic and anaerobic glycolysis in minced tumour tissue, which was the first
experimental demonstration of its anti-tumour effect.
By 1940, so many different lines of research were being pursued simultaneously,
that they are more easily followed if they are traced individually.
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THE DEVELOPMENT OF THE NITROGEN MUSTARDS
During the Second World War, much intensive research was done on gas warfare,
one ofthe end results being the synthesis ofnitrogen mustard, and sulphide mustard.
Much work was carried out on their actions, in an attempt to develop an antidote.
They were found to have, amongst their other actions, a cytotoxic effect on prolifer-
ating cells. This action was scrutinized, but was found to be quite different from the
action of any known chemical, though in some respects, to be like that ofradiation.
The work done in this field remained secret until 1946, when Gilman and Philips27
published the results oftheir investigations on nitrogen and sulphur mustards. They
concluded that the latter were too toxic to use clinically, but that nitrogen mustard
was of potential value, though its mode of action was not fully understood. In the
same year, Rhoads,28 an important contributor to the field, warned that nitrogen
mustard had only so far been used experimentally on advanced carcinomas, and that
it had not produced a cure ofany tumour on which it had been used.
Buttheearlyresults were sufficiently favourable to stimulateintensive investigations
of applications for this drug, for here was a faint hope that untreatable cases might
become treatable. Many series of cases were published describing its effect in many
varieties ofcancer. The organic chemists were also stimulated to produce an analogue
which would be as effective, but easier to administer, and less toxic. It is impossible
to enumerate all the compounds tested, but it is interesting to examine a few. The use
ofTEM(Triethylenemelamine) wasdescribed byPhilipsandThiersch.29 Thoughithad
been in use for many years in the textile industry for improving the finish of rayon
fabrics, it was only discovered medically in 1950 during an intensive search for
cytotoxic agents. An important group of compounds, the phosphoramides, was
synthesized by the American Cyanamid Research Laboratories. Activity against
rodent tumours was first described in 1951, and during the subsequent four years,
a co-ordinated programme was organized to find the best analogue, the most effective
dose and route of administration, and in which tumours it was of benefit.80
'Urethane' (ethyl carbamate) was, as previously noted, found by Warburg in 1910
to inhibit cell division in sea urchins. 'Phenyl urethane' and its derivatives were in-
vestigated in 1929 (Dustin et al.)3' and found to affect mitosis. In 1939 Lef6vres'
described the effects of 'phenylurethane' asbeing similar to those ofcolchicine on the
roots of seedlings. This work was followed up by various authors, and in 1943,
clinical trials were started in the Royal Cancer Hospital. During the next few years,
many trials were carried out with it and various analogues by Haddow et al.,31 but
by 1950 it had virtually fallen out of use, superseded by the development ofso many
other chemotherapeutic agents, whose discovery it had helped to stimulate.
THE CONCEPT OF THE ANTI-METABOLITE
One ofthe most interesting phases ofmodern cancer chemotherapy arose from the
concept developed by Woods82 in 1940. He was working on the ability of sulphona-
mides to inhibit bacterial growth. He suggested that this was brought about by the
blockage of metabolic pathways by competitive inhibition. Lewisohn3o showed that
there was regression of mouse mammary tumours treated with a fermentation factor
from L. casei, found later to be folic acid (Hutchings etal., 1944).Y3 It was synthesized
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in 1946 (Subba Row et al.)34 and in the next year was tried in patients with dis-
seminated carcinoma. The most interesting effect was found when it was given to the
patients with acuteleukaemia, whenitcaused stimulation ofvisceral and marrowcells.
This was called the 'acceleration' phenomenon. The logical conclusion was drawn that
a folic acid antagonist should therefore retard the leukaemic process. With the help
of a drug company (American Cyanamid Company), Farber and his workers tried a
series of antagonists on children with acute leukaemia. The first complete drug-
induced remissions were reported in 1948 with Aminopterin (4-aminopteroylglutamic
acid).30 After this, laboratory studies were carried out to determine its mode ofaction
-the inhibition ofthe conversion offolic acid to folinic acid is its main effect. Many
other compounds have been tried, but the only effective ones are closely related to
Aminopterin. It was after this work that the problem of tumour resistance became
relevant, and it was found that once a tumour became resistant to Aminopterin, it
was also resistant to its analogues.
This led to the first pre-planned research conducted by Hitchings and associates
for an anti-cancer drug with a specific effect.30 It had been shown that free purines
may be incorporated in nucleotide synthesis, so substituted purines were synthesized.
Diaminopurine was the first, but proved disappointing in use. 6-mercaptopurine was
introduced in 1952 (Elion et al.).35 It was subjected to animal trials, and finally,
clinical use, where it has been found to be of most value in acute leukaemia. Several
analogues have been developed, but have no clinical advantage, suffer from the
drawback of cross resistance, and some are positively harmful.
Following this most successful line of research, attempts were made to find other
anti-metabolites for blocking other pathways, but unfortunately none of them has
proved to be ofany value.
THE RE-DISCOVERY OF HORMONES IN RELATION TO CANCER
A briefmention mustbemade ofthe use ofsteroids, asthey now play animportant
part in the management of certain forms of cancer. As synthetic products are used,
they may properly be included in this essay. Oestrogen was isolated in the late 1920s
and in 1933, Dodds first succeeded in synthesizing an analogue. In 1940 Huggins
et al.8 reported the results oftheir work on the effect of stilboestrol on the prostate
of dogs, which they extended to benign prostatic hypertrophy, and finally prostatic
carcinoma in man. Haddow and his associates in 19418 also reported favourably the
results of treatment ofprostatic carcinoma with synthetic oestrogens.
Beatson's work on ovariectomy for carcinoma of the breast was not followed up
until 1944, when Huggins and Moulder8 studied the effects of ovariectomy and
adrenalectomy on dogs. Several other workers in the same year reported the results
of ovariectomy in humans, while Haddow and his associates tried the treatment of
advanced carcinomas with synthetic oestrogens. The initial results showed that only
breast carcinoma was affected by this treatment, and even then only temporary
remissions were obtained, without affecting the course of the disease.
Though these results were so disappointing, they were of great theoretical import-
ance, becausetheyshowedthattumourscouldbeinfluencedbyhormones. Theisolation
of the glucocorticoids and ACTH in the 1940s was of tremendous significance to
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the whole ofmedicine, not least chemotherapy. ACTH was the first agent used after
animaltrials in 1949 by Pearson et al.36 on chronic leukaemias. In 1950 Farber et al.37
tried it on acute leukaemias, where it was found to be most effective. Since then, the
synthesis of glucocorticoids has made possible an easily controllable therapy with
minimal side effects, so that now steroid treatment plays a most important part in
the management of acute leukaemia and breast carcinoma, and oestrogens are the
most effective treatment ofprostatic carcinoma.
THE USE OF ANTIBIOTICS
Afairlyrecentinnovation hasbeen the use ofcertain antibiotics. In 1940, Waksman
and Woodruff38 described the inhibition of pathogenic bacteria by soil micro-
organisms. They studied Ps. aeruginosa and the Actinomyces. From Streptomyces
(Actinomyces) antibioticus, they isolated Actinomycin, but this was thought to be too
toxic for clinical use. This work seems to have been forgotten until 1949, when three
different forms of Actinomycin were described by different authors. Actinomycin C
is ofmostinterest (Brockmann etal.)90beingstrongly bacteriostatic and bacteriocidal,
though very toxic. Actinomycin A was shown (Stock 1950)90 to have slight inhibitory
effects on rodent sarcoma, but was too toxic for clinical use. Trials with Actinomycin
C showed that it also was extremely toxic, but that it had, in some cases, a most
beneficial effect in Hodgkin's disease. Waksman later developed (Manaker et al.,
1954)8° a separate, though similar antibiotic, Actinomycin D. This now has a well-
defined place in the treatment ofWilm's tumour, in combination with radiotherapy.
Several other antibiotics have been described, but none ofthem has found a place in
current chemotherapy.
THE TRIAL OF PLANT EXTRACTS
Plant extracts have attracted a certain amount ofattention throughout the years as
a method oftreating cancer. Colchicine was the first to be shown to have a definite
action-depression ofthe bone marrow (Dixon and Malden, 1908)8-but it has since
been found too toxicforclinical use. In an attempt to avoid the toxicity ofcolchicine,
while maintaining its effect, Demecolcin was isolated in 1950 (Santavy and Reich-
stein).39 It has been found to be only effective in myeloid leukaemia, but other, less
toxic, drugs are available. Vincaleukoblastine was isolated in 1958 (Coutts, Beer and
Noble)"8 from Vinca rosea (periwinkle). Its main effect is also on myeloid leukaemia.
One must mention, though briefly, the tremendous contribution made to this
subject, by those working in the field ofchemical carcinogenesis. This has opened the
way for a deeper understanding of cancer, and perhaps an even more important
by-product has been to make available easily reproducible tumours for experimental
work. The development of tissue culture in artificial media by Eagle30 has added
another most valuable tool for studying the effects of drugs on malignant cells.
THE ORGANIZATION OF CONTEMPORARY RESEARCH
A dramatic step forward was taken in 1955 in the United States ofAmerica, with
thefoundation oftheCancerChemotherapy National Service Center. Thiswas formed
by the leading cancer foundations and has set out on one of the most extensive re-
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search programmes the world has ever seen. It has four areas of research. The first
is organicchemistry, involved with the synthesis ofnewcompounds. The secondis the
screening programme, which nowexamines intheregion of50,000drugs ayear. Those
compounds which pass this screen arepassed on to the third stage ofpharmacological
and biochemical investigation, and finally a very few reach the fourth stage ofclinical
investigation.
This has also served to stimulate workers all over the world and it is interesting to
note how many countries have developed their own favourites in the main groups of
drugs, whichcompareverycloselyineffectwitheachother. Butno one, alas, hasmade
arealbreakthrough. The main reasons forthis arethatdespite therapid accumulation
of knowledge and techniques, the underlying cause of cancer has not yet been dis-
covered, and the close similarity between neoplastic and normal cells makes effective
treatment difficult without damaging the host.
CONCLUSION
Is the present situation really as gloomy as this? I think not, for while the downhill
course of some patients is hastened by treatment with cytotoxic agents, and many
are unchanged, many have benefited over the years and though they may ultimately
die from their tumours, they are enabled in the meantime to live more normal and
often prolonged life. Furthermore, nearly all of the newer, effective drugs have been
found as a result ofempirical research, ratherthan scientifically planned programmes.
We are not really so far removed in this search in our basic philosophy, despite all
our advances, from the ancient physicians, for we still do not know the underlying
cause, or causes, of cancer. Our whole concept of the disease is changing and re-
search is branching out in many new directions. One ofthe most interesting from our
point ofview isthe relationship between the tumour and the host. This varies so much
for different tumours that it is possible that specific drugs will have to be developed
for each one.
It is unfortunate that the pessimistic words of Burrows (1767) are still true-
'Although the physicians ofall nations, from the time of Hippocrates to the present,
have, by numberless researches and experiments, made trial ofeverything in nature,
from the most innocent drug to the most virulent poison, both in the mineral and
vegetable kingdoms; yet the disease still baffles the power ofphysic'. But ifprogress
is to be made, we must take courage from Walshe (1846) who, writing on the cure
ofcancer by drugs, said '. . . nothing can be more unphilosophical than to conclude
that it does not exist, because it has not yet been found.'
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